Protagenic Pfcf Ratio from 2010 to 2024

PTIX Stock  USD 0.52  0.03  5.45%   
Protagenic Therapeutics PFCF Ratio yearly trend continues to be fairly stable with very little volatility. PFCF Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Protagenic Therapeutics PFCF Ratio regression line of annual values had significance of  0 and arithmetic mean of (75.48). View All Fundamentals
 
PFCF Ratio  
First Reported
2010-12-31
Previous Quarter
(1.12)
Current Value
(1.06)
Quarterly Volatility
148.81087186
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 87.3 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagenic Therapeutics Correlation against competitors.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

Latest Protagenic Therapeutics' Pfcf Ratio Growth Pattern

Below is the plot of the Pfcf Ratio of Protagenic Therapeutics over the last few years. It is Protagenic Therapeutics' PFCF Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Pfcf Ratio10 Years Trend
Slightly volatile
   Pfcf Ratio   
       Timeline  

Protagenic Pfcf Ratio Regression Statistics

Arithmetic Mean(75.48)
Coefficient Of Variation(197.15)
Mean Deviation115.00
Median(4.79)
Standard Deviation148.81
Sample Variance22,145
Range363
R-Value0.69
Mean Square Error12,362
R-Squared0.48
Significance0
Slope23.09
Total Sum of Squares310,025

Protagenic Pfcf Ratio History

2024 -1.06
2023 -1.12
2022 -3.46
2021 -7.3
2020 -2.01
2019 -7.41
2018 -4.79

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Pfcf Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
PFCF Ratio(1.12)(1.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.